What Is Neupogen Used For?
Neupogen (filgrastim) treats neutropenia, a low white blood cell count that increases infection risk. It stimulates bone marrow to produce neutrophils, the main infection-fighting white blood cells.[1]
Is It Given During Chemotherapy?
Yes, Neupogen is commonly prescribed for chemotherapy-induced neutropenia. Chemo drugs like taxanes or platinum-based agents suppress bone marrow, causing severe neutropenia. Neupogen is injected under the skin starting 24 hours after chemo to shorten neutropenia duration, reduce infection risk, and support dose delivery.[1][2]
How Does It Fit Into Chemo Treatment?
Doctors use it prophylactically for patients at high risk (e.g., those with solid tumors or lymphomas on intense regimens). It's given daily until neutrophil counts recover, typically 2-4 doses per cycle. Guidelines from NCCN and ASCO recommend it when neutropenia risk exceeds 20%.[2]
What Happens Without It During Chemo?
Untreated neutropenia can lead to febrile neutropenia (fever with low counts), requiring hospitalization, antibiotics, or chemo delays. Neupogen cuts hospitalization odds by 40-50% in trials.[1][3]
Side Effects Patients Report with Chemo Use
Common: bone pain (managed with acetaminophen), headache, fatigue. Rare: spleen rupture, acute respiratory distress, allergic reactions. Monitor counts closely; overuse risks leukocytosis.[1]
Alternatives to Neupogen for Chemo Neutropenia
- Neulasta (pegfilgrastim): Longer-acting version, one dose per cycle.
- Zarxio (filgrastim-sndz): Biosimilar, same effect, often cheaper.
- Leukine (sargramostim): Targets different cells, used if filgrastim fails.[2]
| Drug | Dosing Frequency | Cost per Cycle (approx., US) |
|------|-------------------|------------------------------|
| Neupogen | Daily x 4-7 days | $3,000-$5,000 |
| Neulasta | Once | $4,000-$6,000 |
| Zarxio | Daily x 4-7 days | $2,000-$4,000 |
When Does the Patent Expire?
Neupogen's original patents expired in 2015, enabling biosimilars like Zarxio (approved 2015). No active exclusivities block generics as of 2024.4
[1]: https://www.neupogen.com/
[2]: https://www.nccn.org/guidelines (Myeloid Growth Factors)
[3]: https://pubmed.ncbi.nlm.nih.gov/10894670/ (meta-analysis on G-CSF)